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Purpose: The aim of this study was to retrospectively observe and analyze the long-term treatment outcomes of a
total of 140 esophageal cancer patients who were treated with californium-252 (252Cf) neutron brachytherapy (NBT)
in combination with external beam radiotherapy (EBRT) and concurrent chemotherapy (CCT).
Methods and materials: From January 2002 to November 2012, 140 patients with esophageal cancer underwent
NBT in combination with EBRT and CCT. The distribution of the patient numbers over the various cancer stages of
IIA, IIB, and III were 43, 7, and 90, respectively. The total radiation dose to the reference point via NBT was 8–25 Gy-eq in
two to five fractions with one fraction per week. The total dose via EBRT was 50–60 Gy, which was delivered over a
period of five to six weeks with normal fractionation. Fifty-four and 86 patients received tegafur suppositories (TS) and
continuous infusion of fluorouracil (5-Fu) with cisplatin (CDDP), respectively.
Results: The median follow-up time was 42 months. The minimum follow-up was three months, and the maximum
was 106 months. The overall median survival including death from all causes was 29.5 months. The five-year overall
survival rate (OS) and local control (LC) were 33.4% and 55.9%, respectively. The chemotherapy regimen was a factor
that was significantly associated with OS (p = 0.025) according to univariate analysis. The five-year OSs were 27.4% and
44.3% for the PF and TS chemotherapy regimens, respectively. Regarding acute toxicity, no incidences of fistula or
massive bleeding were observed during this treatment period. The incidence of severe, late complications was
related to the PF chemotherapy regimen (p = 0.080).
Conclusions: The clinical data indicated that NBT in combination with EBRT and CRT produced favorable local
control and long-term survival rates for patients with esophageal cancer and that the side effects were tolerable.
A reasonable CRT regimen can decrease the rate of severe, late complications.
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Table 1 Patient and tumor characteristics
Characteristics Total (%) TS PF p value
Gender 0.395
Male 84(60.0) 30(55.6) 54(62.8)
Female 56(40.0) 24(44.4) 32(37.2)
Age(years) 0.028
≤65 86(61.4) 27(50.0) 59(68.6)
>65 54(38.6) 27(50.0) 27(31.4)
The length 0.354
≤5 cm 58(41.4) 25(46.3) 33(38.4)
>5 cm 82(58.6) 29(53.7) 53(61.6)
Tumor location 0.800
Upper 33(23.6) 11(20.4) 22(25.6)
Middle 92(65.7) 38(70.4) 54(62.8)
Lower 15(11.7) 5(9.2) 10(11.6)
T stage 0.026
T2 22(15.7) 13(24.1) 9(10.5)
T3 51(36.4) 22(40.7) 29(33.7)
T4 67(47.9) 19(35.2) 48(55.8)
N stage 0.002
N0 68(48.6) 35(64.8) 33(38.4)
N1 72(51.4) 19(35.2) 53(61.6)
6th AJCC stage 0.007
Iia 43(30.7) 24(44.4) 19(22.1)
Iib 7(5.0) 4(7.4) 3(3.5)
III 90(64.3) 26(48.2) 64(74.4)
RT Dose 0.809
≤66 Gy 89(63.6) 35(64.8) 54(62.8)
≥67 Gy 51(36.4) 19(44.4) 32(37.2)
Abbreviations: CRT = chemotherapy plus radiotherapy; RT = radiotherapy alone;
OS = Overall survival rate; LCR = local control rate.
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In 2013, an estimated 17,990 cases of esophageal cancer
were diagnosed in the United States, and approximately
15,210 people died from this disease [1]. Worldwide, an
estimated 482,000 new esophageal cancer cases were di-
agnosed, and approximately 407,000 deaths occurred in
2008 [2]. Although surgery continues to be the standard
approach for the majority of localized esophageal can-
cers, the cure rates following surgery alone are poor with
three- to five-year survival rates that range from 6% to
35% [3-5]. The management of loco-regional or locally
advanced esophageal cancer has shifted from single mo-
dality surgery or radiation approaches to trimodal ap-
proaches involving the addition of chemotherapy. The
current trimodal approach, which combines chemo-
therapy, radiation therapy, and surgery, has significantly
improved prognoses, and several studies have shown
improved survival rates [6]. However, many patients
cannot tolerate or decline surgery; for such individuals,
definitive concurrent chemoradiotherapy (CCRT) is the
standard approach.
A radiation therapy oncology group study (RTOG
8501) demonstrated a survival benefit of the addition of
platinum-based chemotherapy to radiation compared to
radiation alone for patients with nonsurgical esophageal
cancer [7,8]. Despite improved local, regional, and dis-
tant control and increased survival, approximately 50%
of patients will have persistent local disease or recur-
rence [7-9]. To enhance the local control rate for ad-
vanced cancer, a combined treatment with CRT and a
brachytherapy boost seemed promising. There were a
few published results of external beam radiation (EBRT),
brachytherapy boosts, and concurrent chemotherapy for
meaningful numbers of patients. However, a high inci-
dence of treatment-related esophageal fistulas was ob-
served in the RTOG 92–07 [10]. We present the results
of a retrospective analysis of a large consecutive series of
patients with locally advanced esophageal cancer who
were treated with a multimodal strategy. The main ob-
jective was to assess the overall survival and local con-
trol rates after combined chemotherapy and irradiation
(EBRT plus neutron brachytherapy). We also evaluated




From January 2002 to November 2012 at the Changzhi
Cancer Hospital, a total of 140 consecutive patients with
localized esophageal cancer were referred to our depart-
ment for EBRT and 252Cf neutron brachytherapy (NBT)
and concurrent chemotherapy. Before entry into the
study, all patients underwent a barium swallow and
upper gastrointestinal endoscopy, chest CT scans, B-typeultrasonography of the neck and abdomen, collection of
blood parameters (including hematology), and biochemical
investigations (including liver function tests). The selection
criteria included a Karnofsky performance score ≥80, tu-
mors ≤10 cm in length on endoscopy and/or barium swal-
low, the capability to take semifluid food, no hoarseness of
the voice, no active bleeding, no perforation of the esopha-
gus, no remote metastasis, and no prior malignancy. The
cancers in the lower esophageal sphincter were all iden-
tified near the opening of the sphincter, and no clear
invasion into the stomach was observed. The cancer
stages (T/N/M) were determined based on the CT and
endoscopy results. All of the patients provided informed
consent before treatment, which was in accordance with
the Declaration of Helsinki, and this study was also ap-
proved by the Ethics Committee of Changzhi Cancer
hospital. The demographic data and tumor characteris-
tics of each group are given in Table 1.
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follows: 84 men and 56 women, aged 44–70 years (me-
dian 63), and KPS scores of 90 in 58 patients, and 80 in
82 patients. The main locations of the lesions were upper
thoracic in 33 patients, middle thoracic in 92, and lower
thoracic in 15, and middle thoracic lesions accounted
for 88.3%. The major axis of the lesion was 6.0 cm in
median length with a range of 3.0 to 10 cm. In the
TNM classification, the T-stage was T2 in 22, T3 in 51,
and T4 in 67 patients; the N-stage was N0 in 68, and
N1 in 72 patients. The responses at the time of registra-
tion (i.e., the response to an external irradiation of 50
Gy) were complete responses (CRs) by barium swallow
and endoscopic findings in 98 (70%) patients, partial re-
sponses (PR) in 39 (27.9%), and no change (NC) in
three patients. All patients received concurrent chemo-
therapy with EBRT + NBT. Fifty-four and 86 patients
received TS and PF regimen chemotherapies, respect-
ively. The characteristics of the patients differed be-
tween the TS regimen group and the PF regimen group
(Table 1).
Radiotherapy
The high-LET (252Cf-based) NBT and the low-LET
EBRT were interchangeably implemented over the treat-
ment time period. The EBRT was performed with a 6-
MV linear accelerator. The treatment field size was
determined according to the CT and barium swallow test
results. The two-field technique (one anterior field and
one posterior field) or the three-field technique (one
anterior field and two posterior fields) was used to treat
the upper segment of the esophagus. Only the three-
field technique (one anterior field and two posterior
fields) was used to treat the middle and lower segments
of the esophagus. The upper and lower boundaries of
the treatment field were determined by adding 3–5 cm
from the visible disease area shown on the CT/barium
swallow images. In general, the width of the treatment
field was 6–7 cm, and the total length was approximately
15 cm. The EBRT followed the normal fractionation with
five fractions per week, one fraction per day, and 1.8-2.0
Gy per fraction for a total of 25–30 fractions, and the total
treatment time was five to six weeks. The total dose via
EBRT was 50–60 Gy, which was delivered over a period of
five to six weeks with normal fractionation.
NBT with a one-balloon applicator (Figure 1) was used
in conjunction with the 252Cf LZH-1000 remote after-
loading system (Linden Science and Technology Co,
Shenzhen, China). The physical characteristics of the
252Cf neutron, the characteristics of the applicator, and
the process of NBT have been described in detail by Liu
H [11,12]. The dose was prescribed to the reference
point, which was located 10 mm from the center point
of the source capsule in the transverse direction. Figure 1shows an X-ray image taken while the applicator and the
source were both inserted into the esophagus of a pa-
tient. In Figure 1, the water balloon can clearly be seen
to be filled with an X-ray contrast agent. The dose was
prescribed to the reference point, which was located 10
mm from the center point of the source capsule in the
transverse direction. The total radiation doses (to the
reference point) given to each patient varied between
8–25 Gy-eq in two to five fractions with 4–5 Gy-eq per
fraction per week.
Chemotherapy
Two concurrent chemotherapy regimens were used: 140
patients received concurrent chemoradiotherapy. Fifty-
four patients received tegafur suppositories (TS) of 500
mg/m2 that were given on days 1–14 and days 21–35.
Eighty-six patients received continuous infusion of fluo-
rouracil (5-FU, 750 mg/m2) on days 1 through 5 and
days 29 through 33 with cisplatin (75 mg/m2) given on
days 1 and 29.
Toxicity assessment and follow-up
The patients were examined weekly during the course of
the external beam radiation. Weekly blood tests were
obtained, and any admissions for treatment-related com-
plications were recorded. All adverse events were graded
according to the National Cancer Institute’s Common
Terminology Criteria for Adverse Events, version 3.0
[13]. The patients typically underwent follow-up exami-
nations every 3–6 months after the completion of treat-
ment. Tumor responses and nodal diseases were evaluated
with repeated CT scans, barium swallow studies, and
endoscopy.
Statistical analyses
The patients were grouped according to the different
chemotherapy regimens (TS and PF). Pearson’s chi-
square tests were used to assess the relationships be-
tween the frequency data. The overall survival (OS) time
was calculated from the date of consultation until death
or the last follow-up. Local and regional failures were
defined by persistent and/or recurrent primary tumors
and regional lymph nodes. The time to first failure, time
to local failure, and time to any distant metastases were
calculated from the date of consultation. The overall sur-
vival (OS) and local control (LC) rates were estimated
using the Kaplan-Meier method. Nine factors were
included for the univariate analyses of OS and LC and
included gender, age, Karnofsky performance score
(KPS), tumor location, tumor length, T stage, N stage,
TNM stage, and radiation dose. The log-rank test was
used to assess the survival differences between the
groups. The data were analyzed using SPSS software
(version 20.0, SPSS Inc., Chicago, IL, USA).
Table 2 Local control and overall survival according to
stage and chemotherapy regimen
Characteristics Total TS PF p value
Stage II N = 50 N = 28 N = 22
5-year LC 60.1% 64.8% 53.9% 0.526
5-year OS 35.7% 40.5% 32.4%
Median survival 32.1 months 30.8 months 35.1 months 0.855
Stage III N = 90 N = 26 N = 64
5-year LC 53.3% 56.6% 49.6% 0.244
5-year OS 32.3% 47.1% 25.9%
Median survival 24.0 months 42.4 months 14.6 months 0.015
Total N = 140
5-year LC 55.9% 61.2% 51.1% 0.185
5-year OS 33.4% 44.3% 27.4%
Median survival 29.5 months 37.7 months 18.6 months 0.025
Figure 1 Images (A-D) showing the tumor regression conditions before each of the four NBT treatments under an X-ray treatment-planning
simulator.
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Survival and local control
The median follow-up time was 42 months. The mini-
mum follow-up was three months, and the maximum
was 106 months. The overall median survival including
death from all causes was 29.5 months. The three and
five-year overall survival rates (OS) were 46.3% and
33.4%, respectively. The five-year local control rate for
the entire group was 55.9%. The survival rates, median
survivals, and local control rates (LC) according to stage
are shown in Table 2. As shown in this table, a total of
nine factors were considered and analyzed for their
relevance to overall survival and local control. These
factors included gender, age, tumor length, tumor loca-
tion, chemotherapy regimen, stage T, stage N, AJCC
stage, and radiation dose. Among these factors, only
chemotherapy regimen was found to be relevant to
overall survival (p = 0.025), and none of the factors were
related to local control. The five-year Oss were 27.4%
and 44.3% for the PF and TS chemotherapy regimen,
respectively (p = 0.025).
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As of the date of the last follow-up (March 31, 2013),
the total number of failures (including local recurrences,
remote metastasis, and deaths) was 94 (67.1%). There
were 56 recurrences (40.0%), among which, 53 (37.9%)
were in-field recurrences, and three (2.3%) were out-of-
field recurrences. Among the three out-of-field recur-
rences, one occurred in the supraclavicular lymph nodes,
and two occurred in the intra-abdominal lymph nodes.
A total of 18 cases of remote metastases were found,
among which, the number of metastases to the lungs,
liver, bone and others tissues were five, three, two, and
eight, respectively. A total of nine deaths as results of
fistula and hematemesis were observed. One patient died
of a secondary cancer. A total of 17 deaths were found
to be caused by reasons other than the original cancer
or the radiation treatment.
Treatment toxicity
All 140 patients completed the planned NBT and EBRT
and concurrent chemotherapies. In terms of acute tox-
icity, no perforations were observed during this treat-
ment period. In total, 107 (76.4%) patients developed
Grade 2 hematologic toxicities. Dysphagia was relieved
after the second or third NBT treatment in 126 cases
(90%), and temporary feeding tubes were not required in
the majority of the patients. Esophagitis of Grade 2 or
more as expressed by clinical odynophagia was observed
in 100 cases (71.4%). In total, six patients had Grade ≥ 2
irradiation dermatitis. From the time of treatmentTable 3 Clinical results of external beam radiation, brachythe
Authors (Ref.) Montravadl et al. [15] Sharma et al. [1
No. of pts. 40 100
BT Gy/fraction 10/2 15(group 1)20(g
Interfraction interval 2 wks 1 wks
Applicator diameter 1 cm NS
EBRT Gy/fraction 40-55 Gy/4-6 weeks 50/28
CT (pts) Mito C 10 mg/m2 i.v. Days 1,29;
5-FU 1000 mg/m2/day 3 4 days
5-Fu 500 mg/m2
before brachyth
Fistula (%) 0% 12%
Bleeding (%) NS 4%
Ulcer (%) NS 29%
Stricture (%) 23% 16%
OS(%) 3 yrs 40% 5 yrs 8%(group
5 yrs 23%(group
LC (%) 85% Complete response;
78% Local control
NS
RTOG: Radiation Therapy Oncology Group; EBRT: external beam radiation therapy; HDR
C; DDP: cisplatin; 5-FU: 5-fluorouracil, TS: tegafur suppositories.completion to the development of local-regional recur-
rence or death at the follow-up time, four (2.9%) and five
(3.6%) patients experienced fistulas and massive bleeding,
respectively. As shown in Table 2, the incidence of severe,
late complications was related to the PF chemotherapy regi-
men (8/86, 9.3%) compared to the TS regimen (1/54,1.9%;
p = 0.080). In total, 75.0% of the patients resumed normal
swallowing, and 3.6% (5/140) had some residual dysphagia
(non-malignant) that required intermittent dilatation. The
other acute toxicities and late complications were not
significantly related to higher total doses or the receipt
of different CCRT regimens.
Discussion
To our knowledge, this is the first reported clinical ex-
perience of the treatment of esophageal cancers using
NBT, EBRT, and concurrent chemotherapy. The safety
and efficacy of this comprehensive treatment appear
promising. We also found that, first, NBT + EBRT and
concurrent chemotherapy is safe and beneficial in terms
of local control in the radical treatment of patients with
esophageal cancer, and second, the OS rate was signifi-
cantly increased, and the late complication rate was sig-
nificantly decreased in patients who received the TS
chemotherapy regimen.
Prior to this report, the published results related to ex-
ternal beam radiation, brachytherapy boost, and concur-
rent chemotherapy in a meaningful number of patients
have been few [14]. Table 3 summarizes these experiences
along with our own. The present study documented norapy boost, and concurrent chemotherapy
6] RTOG9207 [14] Present study
50 140
roup 2)/1 15/3 8-25/2-5
1 wks 1 wks
4-6 mm 0.9 cm
50 Gy/5 wks 50-60 Gy/5-6 wks
, 12 h
erapy
DDP 75 mg/m2 Day
1 Wk 1,5,8,11
TS) 500 mg/m2 given on days
1–14 and days 21–35, or DDP
75 mg/m2 Day 1 Wk 1,5, 5-FU
750 mg/m2/day, days 1–5,
Wk 1,5
5-FU 1000 mg/m2/day











: high-dose-rate; NS: not specified; Adenoma: adenocarcinoma; Mito C: mitomycin
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comparison to the other reports is hampered by the differ-
ences in staging, classification, response end points, and
the duration of follow-up. Differences in treatment regi-
mens or sequencing might account for some of the ob-
served differences in toxicity. The present study showed
survival benefits from the addition of NBT to EBRT and
concurrent chemotherapy in the treatment of locally ad-
vanced disease that resulted in short-term effects, and
these findings are similar to those in the reports of
Montravadl et al. [15] and Sharma et al. [16]. This treat-
ment strategy resulted in better long-term survival and
local control as other authors have reported [14-16].
The primary reason for these effects is that the inci-
dence of late, severe complications was reduced signifi-
cantly by this treatment strategy.
The incidence of late, severe complications was signifi-
cantly related to the factors of higher total dose and
brachytherapy dose. In addition to the dose factors, the
combined treatment with chemotherapy also significantly
increased the incidence of relevant, late complications.
Atsunori Yorozu reported that treatment-related esopha-
geal ulcerations or strictures occurred in 18 patients (34%)
in a CRT group compared to 12% of patients in an RT
group (p = 0.013) [17]. The RTOG 92-07 [14] documented
treatment-related esophageal fistulas in 12% of the pa-
tients. In comparison, no treatment-related esophageal
fistulas were reported in several other series of patients
who received BT and EBRT without chemotherapy [18-21].
The RTOG 92-07 [14] reported that increased courses of
chemotherapy and chemotherapy concurrent with brachy-
therapy might significantly improve the incidence of late,
severe complications. In the present study, the PF regimen
significantly increased the rate of severe, late complication
compared to the TS regimen (p = 0.080). In our experience,
CCRT exhibited very low toxicity, which permitted nearly
all of the patients to complete EBRT followed, when indi-
cated, by a brachytherapy boost. The reasons that our tox-
icity scores were lower than those of other reports are
probably due to the relatively lower mean dose per fraction
of brachytherapy boost and the fact that we utilized ex-
tremely individualized treatment schedules that involved
subsequent esophagography re-evaluations after every frac-
tion that were used to decide whether the next fraction
should be given. In the present study, the incidence of
severe, late complications in the CRT group was low. This
finding is attributable to several main reasons. First, the
chemotherapy regimens were simple, and the majority of
patients received the TS alone and lower PF dosage regi-
mens. Second, the concurrent chemotherapy doses were
lower than those that are used in normal chemotherapy-
alone regimens, which might result in radiotherapy
sensitization. Third, we believe that there are at least two
factors that made the 252Cf-based NBT more effectivethan the 192Ir-based HDR, particularly in the treatment of
locally advanced esophageal cancer. The first factor is re-
lated to the high-LET nature of fission neutrons, which
made them much more effective (compared to the low-
LET X-ray) in killing the hypoxic tumor cells in the locally
advanced cancers. The second factor is related to the fact
that water is an effective neutron attenuator that can be
conveniently injected into the source applicator during
treatment to reduce the neutron dose to the nearby nor-
mal tissue. Because there is a significant difference in the
elasticities of normal tissue and tumor tissue, the proper
injection of water into the source applicator can effectively
push away the nearby normal tissue while still keeping the
tumor tissue close to the source. We estimate that 1 cm of
water can reduce the neutron dose by approximately 15%.
Conclusion
In summary, we believe that NBT + EBRT with concur-
rent chemotherapy is a safe and effective treatment option
for patients with thoracic esophageal cancer. Selected pa-
tients who were treated with combined chemoradiother-
apy and neutron brachytherapy boost achieved better
local control. We recommend a regimen of chemotherapy
with TS alone.
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